239 studies found for:    Thrombocytopenia: Clinical Trials
Show Display Options
Rank Status Study
21 Completed
Has Results
Clinical Trial for Non-responders Who Previously Participated in Eltrombopag Studies TPL 103922 or TPL 108390
Condition: Hepatitis C
Interventions: Drug: Eltrombopag;   Drug: Antiviral therapy
22 Active, not recruiting Eltrombopag in Thrombocytopenic Chronic Lymphocytic Leukemia (CLL) Patients (CLL2S Study of GCLLSG)
Conditions: Chronic Lymphocytic Leukemia;   Thrombocytopenia
Interventions: Drug: Placebo;   Drug: Eltrombopag
23 Recruiting Study to Reveal if Fibrinogen Treatment Effects Blood Clotting Better Than a Platelet Transfusion
Conditions: Blood Platelet Transfusion;   Blood Clotting
Intervention: Drug: Administration of platelet concentrate and taking blood samples
24 Unknown  Secondary Prophylaxis in Non-Hodgkin Lymphoma (NHL) and Chemotherapy-induced Thrombocytopenia
Condition: Non-Hodgkin Lymphoma
Intervention: Drug: Romiplostim
25 Completed
Has Results
Ofatumumab With Fludarabine and Cyclophosphamide in B-CLL Patients
Condition: Leukaemia, Lymphocytic, Chronic
Interventions: Drug: Ofatumumab 500mg;   Drug: Ofatumumab 1000mg;   Drug: Fludarabine;   Drug: Cyclophosphamide
26 Recruiting A Trial of Eltrombopag or Intravenous Immune Globulin Before Surgery for Immune Thrombocytopenia Patients
Condition: Immune Thrombocytopenic Purpura
Interventions: Drug: Eltrombopag;   Drug: IVIG infusion
27 Not yet recruiting Milk-only Lactation Study for Patients on Eltrombopag
Condition: Thrombocytopaenia
Intervention: Drug: eltrombopag
28 Recruiting A Safety and Efficacy Study of Eltrombopag in Subjects With AML
Condition: Leukaemia, Acute
Interventions: Drug: Daunorubicin;   Drug: Cytarabine;   Drug: Eltrombopag;   Drug: Placebo
29 Completed
Has Results
First Line IRESSA™ Versus Carboplatin/Paclitaxel in Asia
Condition: Non-Small Cell Lung Cancer
Interventions: Drug: Gefitinib;   Drug: Carboplatin;   Drug: Paclitaxel
30 Unknown  High-dose Dexamethasone Versus Conventional Dose Prednisone for Initial Treatment of Primary Immune Thrombocytopenia (ITP)
Condition: Purpura, Thrombocytopenic, Idiopathic
Interventions: Drug: Conventional-dose prednisone group;   Drug: High-dose dexamethasone group
31 Enrolling by invitation A Randomized, Double Blind, Placebo-controlled Study to Assess the Efficacy and Safety of Eltrombopag as a Rescue of Isolated Chemotherapy-induced Thrombocytopenia in Patients With Gynecologic Cancer
Condition: Gynecologic Cancer
Interventions: Drug: Eltrombopag;   Drug: Placebo
32 No longer available Expanded Access Trial of Plant Expressed Recombinant Glucocerebrosidase (prGCD) in Patients With Gaucher Disease
Condition: Gaucher Disease
Intervention: Drug: Plant cell expressed recombinant glucocerebrosidase (prGCD)
33 Completed PROphylaxis for ThromboEmbolism in Critical Care Trial (PROTECT)
Conditions: Critical Illness;   Deep Venous Thrombosis
Interventions: Drug: LMWH (Fragmin, dalteparin);   Drug: Unfractionated Heparin
34 Recruiting PROSPER: PostpaRtum PrOphylaxiS for PE Randomized Control Trial Pilot
Conditions: Venous Thromboembolism;   Postpartum
Intervention: Drug: Dalteparin Sodium
35 Recruiting Phase IIa Trial of ALXN1007 for the Treatment of Non-criteria Manifestations of Antiphospholipid Syndrome
Condition: Antiphospholipid (aPL)-Positive
Intervention: Biological: Study Drug- ALXN1007
36 Recruiting A Long-term Safety Study of Eltrombopag in Pediatric Patients With Chronic Immune (Idiopathic) Thrombocytopenic Purpura (ITP)
Condition: Purpura, Thrombocytopenic, Idiopathic
Interventions: Drug: Eltrombopag Tablets;   Drug: Eltrombopag PfOS
37 Completed PROphylaxis for ThromboEmbolism in Critical Care Trial (PROTECT Pilot)
Conditions: Critically Ill;   Deep Venous Thrombosis
Intervention: Drug: Fragmin (Dalteparin) LMWH verus Unfractionated Heparin (UFH)
38 Completed Efficacy and Safety Study of Platelets Treated for Pathogen Inactivation and Stored for Up to Seven Days
Condition: Thrombocytopenia
Intervention: Device: Transfusion of Pathogen Inactivated Platelets stored for 6-7 days
39 Terminated
Has Results
Treating Patients With Recurrent PCNSL With Carboplatin/BBBD and Adding Rituxan To The Treatment Regimen
Conditions: Brain and Central Nervous System Tumors;   Drug/Agent Toxicity by Tissue/Organ;   Lymphoma;   Thrombocytopenia
Interventions: Drug: Rituxan;   Drug: Cyclophosphamide;   Drug: Etoposide;   Drug: Etoposide phosphate;   Drug: Carboplatin;   Drug: Sodium thiosulfate;   Drug: Neupogen;   Drug: Neulasta;   Drug: Cytarabine
40 Suspended Romiplostim in Increasing Low Platelet Counts in Patients With Multiple Myeloma Receiving Chemotherapy
Conditions: Refractory Multiple Myeloma;   Stage I Multiple Myeloma;   Stage II Multiple Myeloma;   Stage III Multiple Myeloma;   Thrombocytopenia
Intervention: Biological: romiplostim

Show previous page of results Previous Page (1-20) Studies Shown (21-40) Next Page (41-60) Show next page of results
Indicates status has not been verified in more than two years